Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When the board does convert his salary to cash, do we know what the next ELTP talking point will be or has it not been issued yet? Not privy to what that memo schedule is. Daily, weekly?
Agree. Let’s keep expanding the pipeline, planning to expand the facility/purchase an additional facility, starting internal sales/marketing, on and on and on just to try and take the company private. Makes zero sense. It’s literally so much easier to do little to nothing and let the company flounder. Why personally loan the company your own money to keep it afloat/grow it? You wouldn’t if your ultimate goal was to buy it cheap.
But if that was true, why build the company up at all? Why personally loan them money to help stave off bankruptcy and/or to fuel growth? Just let it flounder and buy it up. Why do anything to potentially make that hostile takeover price higher?
If your theory was correct, why would Nasrat do anything at all to improve the value of the company? Why not just skip the sales and marketing altogether, just contract manufacture or something and that’s it? Make maybe 1-2 million a year in revenues, fire half the staff or more, let the stock drift as close to zero as possible as the company starts to appear “dead” or dying to the outside world and then scoop it up cheap.
He’s clearly not doing that as evidenced by building up sales and marketing division, planning for purchasing or otherwise acquiring additional facilities, continuing to fill the pipeline at all stages of product development and spending millions upon millions in R&D, mentioned possibly selling other companies’ products for additional income… if the stock price responded normally like other stocks do with positive fundamentals/developments, no one would be complaining.
It is indeed difficult for investors to purchase ELTP shares on a Saturday.
I think it’s safe to assume that when approved, generic Oxy will provide more than 3.8 cents to the bottom line.
The question is - is generic Oxy one of 3 the needle movers he mentioned?
Either way, I tend to agree with you. A dip to ~7 million in revenues from ~10 isn’t even terrible either, considering they are building up the sales arm from nothing at all.
I’m good with that. Not sure how feasible it is with current share count though.
No, no I don’t think I will.
Lol such a joke.
Only 1 business day left in that range, still confident??
ELTP the stock has been essentially disconnected from Elite the company, as far as performance goes. $30-40M in revenues now.
Gracias.
$ELTP$
I have a hard time believing these little 100 share, even 1000 share trades are legit retail shareholders. $3, even $30 trades?
Ready for a Dexcel update too but no telling when that happens.
Let’s go!
People love on a sale on anything… except stocks.
Excellent Q
“Want to walk away” lol
So do so?
When do we get abuse study results, next week??
A whistleblower? Lol
Bshr% rising, upward move likely
Yes any company can fail. Some are much more likely to than others. We don’t have anywhere near the crushing debt that Lannett has/had. The recent bank loan Elite obtained to purchase their property is about $12 million, meanwhile Lannett is over half a billion dollars in debt.
Interesting.
Too uncertain right now with sales and marketing division being built from the ground up. Need a few quarters to see if we can meet/exceed historical numbers.
That’s old, from 2016 right? I know someone posted about the more recent ruling on Purdue patents and Intas pharma or whatever it’s called.
I still want to know how the generic Oxy ANDA works. We filed in what, 2017 but then the FDA came out with abuse study requirements + the patent issues? Once we complete the insufflation study Nasrat referenced, does the FDA then start processing that application toward approval? Or are we still bound by Purdue’s patents?
Anyone know?
CONGRATS
k.
CONGRATS AGAIN, CMDAWG!
So we don’t want people buying shares? Lol ok. Now I’m def confused.
Not sure, gotta see where we land. If I see some panic selling that I don’t feel is warranted, I’d snag low .02s if it got that low. Got some mid 3s and high 2s this year already.
No way to know how the share price will react to the next quarterly/yearly report. We have had revenue gains and profits, some larger than others, in nearly every quarter for how many years now? And the price has still repeatedly declined. So I don’t think it’s crazy to suspect the price could also decline further after we see a drop in revenues while we build up internal sales and marketing division.
Additionally, Roths have relatively low annual contribution limits so trying to time my buys well.
I saw that fat chunk of volume go through, congrats dude!
I’ve got some powder I’m keeping dry in the Roth just in case we see some shenanigans after they report on this current quarter.
Question is, does this open the flood gates for other generic Oxy ANDAs (like ours) to be approved?
Or is this only narrowly applicable to Intas Pharma’s Oxy?
NYSE to Suspend Trading Immediately in Lannett Company, Inc. (LCI) and Commence Delisting Proceedings
April 19, 2023, 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Lannett Company, Inc. (the “Company”) - ticker symbol LCI - from the NYSE. Trading in the Company’s common stock will be suspended immediately.
NYSE Regulation reached its decision to delist the Company’s common stock pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005997/en/
Plus like NH said on the last call, it’s hard to project revenues and such on these products years out when you don’t know what the competitor landscape will look like yet. Maybe a given ANDA is worth the development money spent, maybe not and we end up divesting it.
Well, you don’t know what the stock price would do after announcing and completing a buyout either but you 100% would reduce the supply of shares and that SHOULD lead to a rise in price.
I actually agree and included that as a question. Near all time lows - maybe not right this second but at these levels, once the S&M arm is built and stable….
Buyback will probably never be as cheap, or as easy, or go as far with the money spent as now.
A million bucks is 33,333,333 or thereabouts at .03 right now, maybe less whatever associated costs? Plus the press of doing that could completely change the sentiment.
My man.
Only a couple more days until Elite is officially out on its own for sales and marketing - interested to see how this plays out.
I mean read the board? Lol. Pretty easy to see who.
But I keep being told this company is worthless, so which is it?? LOL.
Literally can’t have it both ways.